ID   TNR6_HUMAN              Reviewed;         335 AA.
AC   P25445; A9UJX4; B6VNV4; Q14292; Q14293; Q14294; Q14295; Q16652;
AC   Q5T9P1; Q5T9P2; Q5T9P3; Q6SSE9;
DT   01-MAY-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1992, sequence version 1.
DT   10-MAY-2017, entry version 217.
DE   RecName: Full=Tumor necrosis factor receptor superfamily member 6;
DE   AltName: Full=Apo-1 antigen;
DE   AltName: Full=Apoptosis-mediating surface antigen FAS;
DE   AltName: Full=FASLG receptor;
DE   AltName: CD_antigen=CD95;
DE   Flags: Precursor;
GN   Name=FAS; Synonyms=APT1, FAS1, TNFRSF6;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1713127; DOI=10.1016/0092-8674(91)90614-5;
RA   Itoh N., Yonehara S., Ishii A., Yonehara M., Mizushima S.,
RA   Sameshima M., Hase A., Seto Y., Nagata S.;
RT   "The polypeptide encoded by the cDNA for human cell surface antigen
RT   Fas can mediate apoptosis.";
RL   Cell 66:233-243(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND PROTEIN SEQUENCE OF
RP   226-240; 269-291 AND 321-335.
RX   PubMed=1375228;
RA   Oehm A., Behrmann I., Falk W., Pawlita M., Maier G., Klas C.,
RA   Li-Weber M., Richards S., Dhein J., Trauth B.C., Ponstingl H.,
RA   Krammer P.H.;
RT   "Purification and molecular cloning of the APO-1 cell surface antigen,
RT   a member of the tumor necrosis factor/nerve growth factor receptor
RT   superfamily. Sequence identity with the Fas antigen.";
RL   J. Biol. Chem. 267:10709-10715(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 3; 4 AND 6), AND TISSUE
RP   SPECIFICITY.
RX   PubMed=7575433; DOI=10.1042/bj3100957;
RA   Liu C., Cheng J., Mountz J.D.;
RT   "Differential expression of human Fas mRNA species upon peripheral
RT   blood mononuclear cell activation.";
RL   Biochem. J. 310:957-963(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3 AND 6), AND FUNCTION.
RX   PubMed=7533181;
RA   Cascino I., Fiucci G., Papoff G., Ruberti G.;
RT   "Three functional soluble forms of the human apoptosis-inducing Fas
RT   molecule are produced by alternative splicing.";
RL   J. Immunol. 154:2706-2713(1995).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 7).
RX   PubMed=8598453;
RA   Cascino I., Papoff G., De Maria R., Testi R., Ruberti G.;
RT   "Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling
RT   domain protects tumor cells from Fas-mediated apoptosis.";
RL   J. Immunol. 156:13-17(1996).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 4 AND 5).
RX   PubMed=8648105;
RA   Papoff G., Cascino I., Eramo A., Starace G., Lynch D.H., Ruberti G.;
RT   "An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants
RT   prevents cell death in vitro.";
RL   J. Immunol. 156:4622-4630(1996).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ALPS1A SER-262.
RX   PubMed=17336828; DOI=10.1016/j.imbio.2006.12.003;
RA   Del-Rey M.J., Manzanares J., Bosque A., Aguilo J.I., Gomez-Rial J.,
RA   Roldan E., Serrano A., Anel A., Paz-Artal E., Allende L.M.;
RT   "Autoimmune lymphoproliferative syndrome (ALPS) in a patient with a
RT   new germline Fas gene mutation.";
RL   Immunobiology 212:73-83(2007).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5).
RC   TISSUE=Peripheral blood lymphocyte;
RA   Schaetzlein C.E., Poehlmann R., Philippsen P., Eibel H.;
RL   Submitted (JUN-1995) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   De La Calle-Martin O.;
RL   Submitted (OCT-2008) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS THR-16; ILE-122 AND
RP   ILE-305.
RG   NIEHS SNPs program;
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA   Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA   Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA   Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA   Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA   Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA   Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA   Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA   Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA   Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA   Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA   Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA   Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA   Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA   Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA   Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA   Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Urinary bladder;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [15]
RP   INTERACTION WITH RIPK1.
RX   PubMed=7538908; DOI=10.1016/0092-8674(95)90072-1;
RA   Stanger B.Z., Leder P., Lee T.-H., Kim E., Seed B.;
RT   "RIP: a novel protein containing a death domain that interacts with
RT   Fas/APO-1 (CD95) in yeast and causes cell death.";
RL   Cell 81:513-523(1995).
RN   [16]
RP   INTERACTION WITH FEM1B.
RX   PubMed=10542291; DOI=10.1074/jbc.274.45.32461;
RA   Chan S.-L., Tan K.-O., Zhang L., Yee K.S.Y., Ronca F., Chan M.-Y.,
RA   Yu V.C.;
RT   "F1Aalpha, a death receptor-binding protein homologous to the
RT   Caenorhabditis elegans sex-determining protein, FEM-1, is a caspase
RT   substrate that mediates apoptosis.";
RL   J. Biol. Chem. 274:32461-32468(1999).
RN   [17]
RP   INTERACTION WITH FAIM2.
RX   PubMed=10535980; DOI=10.1073/pnas.96.22.12667;
RA   Somia N.V., Schmitt M.J., Vetter D.E., Van Antwerp D., Heinemann S.F.,
RA   Verma I.M.;
RT   "LFG: an anti-apoptotic gene that provides protection from fas-
RT   mediated cell death.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:12667-12672(1999).
RN   [18]
RP   SPLICE ISOFORM(S) THAT ARE POTENTIAL NMD TARGET(S).
RX   PubMed=14759258; DOI=10.1186/gb-2004-5-2-r8;
RA   Hillman R.T., Green R.E., Brenner S.E.;
RT   "An unappreciated role for RNA surveillance.";
RL   Genome Biol. 5:R8.1-R8.16(2004).
RN   [19]
RP   INTERACTION WITH BRE.
RX   PubMed=15465831; DOI=10.1074/jbc.M408678200;
RA   Li Q., Ching A.K.-K., Chan B.C.-L., Chow S.K.-Y., Lim P.-L.,
RA   Ho T.C.-Y., Ip W.-K., Wong C.-K., Lam C.W.-K., Lee K.K.-H.,
RA   Chan J.Y.-H., Chui Y.-L.;
RT   "A death receptor-associated anti-apoptotic protein, BRE, inhibits
RT   mitochondrial apoptotic pathway.";
RL   J. Biol. Chem. 279:52106-52116(2004).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-209, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [22]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-118.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [23]
RP   INTERACTION WITH FADD.
RX   PubMed=21109225; DOI=10.1016/j.ajhg.2010.10.028;
RA   Bolze A., Byun M., McDonald D., Morgan N.V., Abhyankar A.,
RA   Premkumar L., Puel A., Bacon C.M., Rieux-Laucat F., Pang K.,
RA   Britland A., Abel L., Cant A., Maher E.R., Riedl S.J., Hambleton S.,
RA   Casanova J.L.;
RT   "Whole-exome-sequencing-based discovery of human FADD deficiency.";
RL   Am. J. Hum. Genet. 87:873-881(2010).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [26]
RP   GLYCOSYLATION AT THR-28, STRUCTURE OF CARBOHYDRATES, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=22171320; DOI=10.1074/mcp.M111.013649;
RA   Halim A., Nilsson J., Ruetschi U., Hesse C., Larson G.;
RT   "Human urinary glycoproteomics; attachment site specific analysis of
RT   N-and O-linked glycosylations by CID and ECD.";
RL   Mol. Cell. Proteomics 0:0-0(2011).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-225, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [28]
RP   STRUCTURE BY NMR OF 218-335.
RX   PubMed=8967952; DOI=10.1038/384638a0;
RA   Huang B., Eberstadt M., Olejniczak E.T., Meadows R.P., Fesik S.W.;
RT   "NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain.";
RL   Nature 384:638-641(1996).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (2.73 ANGSTROMS) OF 223-335 IN COMPLEX WITH
RP   FADD, FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   TYR-291 AND ILE-313.
RX   PubMed=19118384; DOI=10.1038/nature07606;
RA   Scott F.L., Stec B., Pop C., Dobaczewska M.K., Lee J.J., Monosov E.,
RA   Robinson H., Salvesen G.S., Schwarzenbacher R., Riedl S.J.;
RT   "The Fas-FADD death domain complex structure unravels signalling by
RT   receptor clustering.";
RL   Nature 457:1019-1022(2009).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 230-254 IN COMPLEX WITH
RP   CALM, AND CALMODULIN-BINDING.
RX   PubMed=24914971; DOI=10.1107/S1399004714006919;
RA   Jiang T., Cao P., Gong Y., Yu H.J., Gui W.J., Zhang W.T.;
RT   "Structural insights into the mechanism of calmodulin binding to death
RT   receptors.";
RL   Acta Crystallogr. D 70:1604-1613(2014).
RN   [31]
RP   VARIANT ALPS1A PRO-241.
RX   PubMed=7540117; DOI=10.1016/0092-8674(95)90013-6;
RA   Fisher G.H., Rosenberg F.J., Straus S.E., Dale J.K., Middleton L.A.,
RA   Lin A.Y., Strober W., Lenardo M.J., Puck J.M.;
RT   "Dominant interfering Fas gene mutations impair apoptosis in a human
RT   autoimmune lymphoproliferative syndrome.";
RL   Cell 81:935-946(1995).
RN   [32]
RP   VARIANT ALPS1A TYR-260.
RX   PubMed=8929361; DOI=10.1056/NEJM199611283352204;
RA   Drappa J., Vaishnaw A.K., Sullivan K.E., Chu J.-L., Elkon K.B.;
RT   "Fas gene mutations in the Canale-Smith syndrome, an inherited
RT   lymphoproliferative disorder associated with autoimmunity.";
RL   N. Engl. J. Med. 335:1643-1649(1996).
RN   [33]
RP   VARIANTS ALPS1A TRP-121 AND CYS-232.
RX   PubMed=9028321;
RA   Bettinardi A., Brugnoni D., Quiros-Roldan E., Malagoli A.,
RA   La Grutta S., Correra A., Notarangelo L.D.;
RT   "Missense mutations in the Fas gene resulting in autoimmune
RT   lymphoproliferative syndrome: a molecular and immunological
RT   analysis.";
RL   Blood 89:902-909(1997).
RN   [34]
RP   VARIANTS ALPS1A ASP-257 AND SER-310.
RX   PubMed=9028957;
RA   Sneller M.C., Wang J., Dale J.K., Strober W., Middelton L.A., Choi Y.,
RA   Fleisher T.A., Lim M.S., Jaffe E.S., Puck J.M., Lenardo M.J.,
RA   Straus S.E.;
RT   "Clinical, immunologic, and genetic features of an autoimmune
RT   lymphoproliferative syndrome associated with abnormal lymphocyte
RT   apoptosis.";
RL   Blood 89:1341-1348(1997).
RN   [35]
RP   VARIANT ALPS1A ALA-28.
RX   PubMed=9322534; DOI=10.1053/gast.1997.v113.pm9322534;
RA   Pensati L., Costanzo A., Ianni A., Accapezzato D., Iorio R.,
RA   Natoli G., Nisini R., Almerighi C., Balsano C., Vajro P., Vegnente A.,
RA   Levrero M.;
RT   "Fas/Apo1 mutations and autoimmune lymphoproliferative syndrome in a
RT   patient with type 2 autoimmune hepatitis.";
RL   Gastroenterology 113:1384-1389(1997).
RN   [36]
RP   VARIANTS NON-HODGKIN LYMPHOMA THR-25; PHE-180; LEU-183; ILE-198;
RP   VAL-260; LYS-264; LYS-272; PHE-278 AND ASN-299.
RX   PubMed=9787134;
RA   Groenbaek K., Straten P.T., Ralfkiaer E., Ahrenkiel V., Andersen M.K.,
RA   Hansen N.E., Zeuthen J., Hou-Jensen K., Guldberg P.;
RT   "Somatic Fas mutations in non-Hodgkin's lymphoma: association with
RT   extranodal disease and autoimmunity.";
RL   Blood 92:3018-3024(1998).
RN   [37]
RP   VARIANT ALPS1A VAL-260.
RX   PubMed=9821419; DOI=10.1016/S0022-3476(98)70102-7;
RA   Infante A.J., Britton H.A., DeNapoli T., Middelton L.A., Lenardo M.J.,
RA   Jackson C.E., Wang J., Fleisher T., Straus S.E., Puck J.M.;
RT   "The clinical spectrum in a large kindred with autoimmune
RT   lymphoproliferative syndrome caused by a Fas mutation that impairs
RT   lymphocyte apoptosis.";
RL   J. Pediatr. 133:629-633(1998).
RN   [38]
RP   VARIANTS ALPS1A LYS-241 AND GLN-250.
RX   PubMed=10090885; DOI=10.1086/302333;
RA   Jackson C.E., Fischer R.E., Hsu A.P., Anderson S.M., Choi Y., Wang J.,
RA   Dale J.K., Fleisher T.A., Middelton L.A., Sneller M.C., Lenardo M.J.,
RA   Straus S.E., Puck J.M.;
RT   "Autoimmune lymphoproliferative syndrome with defective Fas: genotype
RT   influences penetrance.";
RL   Am. J. Hum. Genet. 64:1002-1014(1999).
RN   [39]
RP   VARIANTS ALPS1A LEU-249; PRO-250; ASP-253; SER-253; ARG-259; LYS-270
RP   AND LYS-272.
RX   PubMed=10515860;
RA   Rieux-Laucat F., Blachere S., Danielan S., De Villartay J.P.,
RA   Oleastro M., Solary E., Bader-Meunier B., Arkwright P., Pondare C.,
RA   Bernaudin F., Chapel H., Nielsen S., Berrah M., Fischer A.,
RA   Le Deist F.;
RT   "Lymphoproliferative syndrome with autoimmunity: A possible genetic
RT   basis for dominant expression of the clinical manifestations.";
RL   Blood 94:2575-2582(1999).
RN   [40]
RP   VARIANT ALPS1A GLY-272.
RX   PubMed=10340403; DOI=10.1016/S0301-472X(99)00033-8;
RA   Peters A.M., Kohfink B., Martin H., Griesinger F., Wormann B.,
RA   Gahr M., Roesler J.;
RT   "Defective apoptosis due to a point mutation in the death domain of
RT   CD95 associated with autoimmune lymphoproliferative syndrome, T-cell
RT   lymphoma, and Hodgkin's disease.";
RL   Exp. Hematol. 27:868-874(1999).
RN   [41]
RP   VARIANTS ALPS1A ARG-82; PRO-250; GLY-260 AND ILE-270.
RX   PubMed=9927496; DOI=10.1172/JCI5121;
RA   Vaishnaw A.K., Orlinick J.R., Chu J.-L., Krammer P.H., Chao M.V.,
RA   Elkon K.B.;
RT   "The molecular basis for apoptotic defects in patients with CD95
RT   (Fas/Apo-1) mutations.";
RL   J. Clin. Invest. 103:355-363(1999).
RN   [42]
RP   VARIANTS SQUAMOUS CELL CARCINOMA SER-118; ARG-178 AND ASP-255.
RX   PubMed=10620127; DOI=10.1046/j.1523-1747.2000.00819.x;
RA   Lee S.H., Shin M.S., Kim H.S., Park W.S., Kim S.Y., Jang J.J.,
RA   Rhim K.J., Jang J., Lee H.K., Park J.Y., Oh R.R., Han S.Y., Lee J.H.,
RA   Lee J.Y., Yoo N.J.;
RT   "Somatic mutations of Fas (Apo-1/CD95) gene in cutaneous squamous cell
RT   carcinoma arising from a burn scar.";
RL   J. Invest. Dermatol. 114:122-126(2000).
RN   [43]
RP   VARIANTS ALPS1A PRO-241; VAL-260; ILE-270 AND GLY-272.
RX   PubMed=11418480; DOI=10.1182/blood.V98.1.194;
RA   Straus S.E., Jaffe E.S., Puck J.M., Dale J.K., Elkon K.B.,
RA   Roesen-Wolff A., Peters A.M.J., Sneller M.C., Hallahan C.W., Wang J.,
RA   Fischer R.E., Jackson C.M., Lin A.Y., Baeumler C., Siegert E.,
RA   Marx A., Vaishnaw A.K., Grodzicky T., Fleisher T.A., Lenardo M.J.;
RT   "The development of lymphomas in families with autoimmune
RT   lymphoproliferative syndrome with germline Fas mutations and defective
RT   lymphocyte apoptosis.";
RL   Blood 98:194-200(2001).
RN   [44]
RP   CHARACTERIZATION OF VARIANTS ALPS1A CYS-232; GLN-250; ASP-257;
RP   TYR-260; VAL-260; LYS-270 AND LYS-272, AND MUTAGENESIS OF ARG-250;
RP   GLU-261; GLN-283 AND LYS-287.
RX   PubMed=20935634; DOI=10.1038/nsmb.1920;
RA   Wang L., Yang J.K., Kabaleeswaran V., Rice A.J., Cruz A.C., Park A.Y.,
RA   Yin Q., Damko E., Jang S.B., Raunser S., Robinson C.V., Siegel R.M.,
RA   Walz T., Wu H.;
RT   "The Fas-FADD death domain complex structure reveals the basis of DISC
RT   assembly and disease mutations.";
RL   Nat. Struct. Mol. Biol. 17:1324-1329(2010).
CC   -!- FUNCTION: Receptor for TNFSF6/FASLG. The adapter molecule FADD
CC       recruits caspase-8 to the activated receptor. The resulting death-
CC       inducing signaling complex (DISC) performs caspase-8 proteolytic
CC       activation which initiates the subsequent cascade of caspases
CC       (aspartate-specific cysteine proteases) mediating apoptosis. FAS-
CC       mediated apoptosis may have a role in the induction of peripheral
CC       tolerance, in the antigen-stimulated suicide of mature T-cells, or
CC       both. The secreted isoforms 2 to 6 block apoptosis (in vitro).
CC       {ECO:0000269|PubMed:19118384, ECO:0000269|PubMed:7533181}.
CC   -!- SUBUNIT: Binds DAXX. Interacts with HIPK3. Part of a complex
CC       containing HIPK3 and FADD (By similarity). Binds RIPK1 and FAIM2
CC       (PubMed:7538908, PubMed:10535980). Interacts with BRE and FEM1B
CC       (PubMed:10542291, PubMed:15465831). Interacts with FADD
CC       (PubMed:21109225, PubMed:19118384). Interacts directly (via DED
CC       domain) with NOL3 (via CARD domain); inhibits death-inducing
CC       signaling complex (DISC) assembly by inhibiting the increase in
CC       FAS-FADD binding induced by FAS activation (By similarity).
CC       Interacts with CALM (PubMed:24914971).
CC       {ECO:0000250|UniProtKB:Q63199, ECO:0000269|PubMed:10535980,
CC       ECO:0000269|PubMed:10542291, ECO:0000269|PubMed:15465831,
CC       ECO:0000269|PubMed:19118384, ECO:0000269|PubMed:21109225,
CC       ECO:0000269|PubMed:24914971, ECO:0000269|PubMed:7538908}.
CC   -!- INTERACTION:
CC       Self; NbExp=3; IntAct=EBI-494743, EBI-494743;
CC       P62158:CALM3; NbExp=4; IntAct=EBI-494743, EBI-397435;
CC       Q14790:CASP8; NbExp=14; IntAct=EBI-494743, EBI-78060;
CC       Q03135:CAV1; NbExp=3; IntAct=EBI-494743, EBI-603614;
CC       Q9UER7:DAXX; NbExp=3; IntAct=EBI-494743, EBI-77321;
CC       Q13158:FADD; NbExp=33; IntAct=EBI-494743, EBI-494804;
CC       P48023:FASLG; NbExp=4; IntAct=EBI-494743, EBI-495538;
CC       Q99683:MAP3K5; NbExp=2; IntAct=EBI-494743, EBI-476263;
CC       P12815:Pdcd6 (xeno); NbExp=2; IntAct=EBI-494743, EBI-309164;
CC       P29590:PML; NbExp=4; IntAct=EBI-494743, EBI-295890;
CC       Q15156:PML-RAR; NbExp=6; IntAct=EBI-494743, EBI-867256;
CC       Q12923:PTPN13; NbExp=3; IntAct=EBI-494743, EBI-355227;
CC       P12931:SRC; NbExp=2; IntAct=EBI-494743, EBI-621482;
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Cell membrane; Single-pass type I
CC       membrane protein.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Secreted.
CC   -!- SUBCELLULAR LOCATION: Isoform 3: Secreted.
CC   -!- SUBCELLULAR LOCATION: Isoform 4: Secreted.
CC   -!- SUBCELLULAR LOCATION: Isoform 5: Secreted.
CC   -!- SUBCELLULAR LOCATION: Isoform 6: Secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=7;
CC       Name=1;
CC         IsoId=P25445-1; Sequence=Displayed;
CC       Name=2; Synonyms=del2, D;
CC         IsoId=P25445-2; Sequence=VSP_006481, VSP_006482;
CC         Note=May be produced at very low levels due to a premature stop
CC         codon in the mRNA, leading to nonsense-mediated mRNA decay.;
CC       Name=3; Synonyms=del3, E;
CC         IsoId=P25445-3; Sequence=VSP_006483, VSP_006484;
CC         Note=May be produced at very low levels due to a premature stop
CC         codon in the mRNA, leading to nonsense-mediated mRNA decay.;
CC       Name=4; Synonyms=B;
CC         IsoId=P25445-4; Sequence=VSP_006485, VSP_006486;
CC         Note=May be produced at very low levels due to a premature stop
CC         codon in the mRNA, leading to nonsense-mediated mRNA decay.;
CC       Name=5; Synonyms=C;
CC         IsoId=P25445-5; Sequence=VSP_006487, VSP_006488;
CC         Note=May be produced at very low levels due to a premature stop
CC         codon in the mRNA, leading to nonsense-mediated mRNA decay.;
CC       Name=6; Synonyms=TMdel, A;
CC         IsoId=P25445-6; Sequence=VSP_006489;
CC       Name=7; Synonyms=FasExo8Del;
CC         IsoId=P25445-7; Sequence=VSP_045235, VSP_045236;
CC         Note=Dominant negative isoform, resistant to Fas-mediated
CC         apoptosis.;
CC   -!- TISSUE SPECIFICITY: Isoform 1 and isoform 6 are expressed at equal
CC       levels in resting peripheral blood mononuclear cells. After
CC       activation there is an increase in isoform 1 and decrease in the
CC       levels of isoform 6. {ECO:0000269|PubMed:7575433}.
CC   -!- DOMAIN: Contains a death domain involved in the binding of FADD,
CC       and maybe to other cytosolic adapter proteins.
CC   -!- PTM: N- and O-glycosylated. O-glycosylated with core 1 or possibly
CC       core 8 glycans. {ECO:0000269|PubMed:19159218,
CC       ECO:0000269|PubMed:22171320}.
CC   -!- DISEASE: Autoimmune lymphoproliferative syndrome 1A (ALPS1A)
CC       [MIM:601859]: A disorder of apoptosis that manifests in early
CC       childhood and results in the accumulation of autoreactive
CC       lymphocytes. It is characterized by non-malignant lymphadenopathy
CC       with hepatosplenomegaly, and autoimmune hemolytic anemia,
CC       thrombocytopenia and neutropenia. {ECO:0000269|PubMed:10090885,
CC       ECO:0000269|PubMed:10340403, ECO:0000269|PubMed:10515860,
CC       ECO:0000269|PubMed:11418480, ECO:0000269|PubMed:17336828,
CC       ECO:0000269|PubMed:20935634, ECO:0000269|PubMed:7540117,
CC       ECO:0000269|PubMed:8929361, ECO:0000269|PubMed:9028321,
CC       ECO:0000269|PubMed:9028957, ECO:0000269|PubMed:9322534,
CC       ECO:0000269|PubMed:9821419, ECO:0000269|PubMed:9927496}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- WEB RESOURCE: Name=Autoimmune Lymphoproliferative Syndrome
CC       Database (ALPSbase); Note=Mutations in TNFRSF6 causing ALPS type
CC       Ia;
CC       URL="https://www.niaid.nih.gov/diseases-conditions/autoimmune-lymphoproliferative-syndrome-alps";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/tnfrsf6/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M67454; AAA63174.1; -; mRNA.
DR   EMBL; X63717; CAA45250.1; -; mRNA.
DR   EMBL; X83490; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; X83491; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; X83492; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; X83493; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; Z47993; CAA88031.1; -; mRNA.
DR   EMBL; Z47994; CAA88032.1; -; mRNA.
DR   EMBL; Z47995; CAA88033.1; -; mRNA.
DR   EMBL; Z66556; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; Z70519; CAA94430.1; -; mRNA.
DR   EMBL; Z70520; CAA94431.1; -; mRNA.
DR   EMBL; AY495076; AAS76663.1; -; mRNA.
DR   EMBL; X89101; CAA61473.1; -; mRNA.
DR   EMBL; FM246458; CAR92543.1; -; mRNA.
DR   EMBL; AK290978; BAF83667.1; -; mRNA.
DR   EMBL; AY450925; AAR08906.1; -; Genomic_DNA.
DR   EMBL; AL157394; CAI13870.1; -; Genomic_DNA.
DR   EMBL; AL157394; CAI13871.1; -; Genomic_DNA.
DR   EMBL; AL157394; CAI13872.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW50151.1; -; Genomic_DNA.
DR   EMBL; BC012479; AAH12479.1; -; mRNA.
DR   CCDS; CCDS7393.1; -. [P25445-1]
DR   CCDS; CCDS7394.1; -. [P25445-6]
DR   CCDS; CCDS7395.1; -. [P25445-7]
DR   PIR; A40036; A40036.
DR   PIR; I37383; I37383.
DR   PIR; I37384; I37384.
DR   PIR; S58662; S58662.
DR   RefSeq; NP_000034.1; NM_000043.5. [P25445-1]
DR   RefSeq; NP_001307548.1; NM_001320619.1.
DR   RefSeq; NP_690610.1; NM_152871.3. [P25445-6]
DR   RefSeq; NP_690611.1; NM_152872.3. [P25445-7]
DR   UniGene; Hs.244139; -.
DR   UniGene; Hs.667309; -.
DR   PDB; 1BZI; Model; -; A=1-335.
DR   PDB; 1DDF; NMR; -; A=218-335.
DR   PDB; 2NA7; NMR; -; A/B/C=171-198.
DR   PDB; 3EWT; X-ray; 2.40 A; E=230-254.
DR   PDB; 3EZQ; X-ray; 2.73 A; A/C/E/G/I/K/M/O=223-335.
DR   PDB; 3THM; X-ray; 2.10 A; F=17-172.
DR   PDB; 3TJE; X-ray; 1.93 A; F=17-172.
DR   PDBsum; 1BZI; -.
DR   PDBsum; 1DDF; -.
DR   PDBsum; 2NA7; -.
DR   PDBsum; 3EWT; -.
DR   PDBsum; 3EZQ; -.
DR   PDBsum; 3THM; -.
DR   PDBsum; 3TJE; -.
DR   ProteinModelPortal; P25445; -.
DR   SMR; P25445; -.
DR   BioGrid; 106851; 101.
DR   DIP; DIP-924N; -.
DR   IntAct; P25445; 48.
DR   MINT; MINT-146256; -.
DR   STRING; 9606.ENSP00000347979; -.
DR   iPTMnet; P25445; -.
DR   PhosphoSitePlus; P25445; -.
DR   SwissPalm; P25445; -.
DR   UniCarbKB; P25445; -.
DR   BioMuta; FAS; -.
DR   DMDM; 119833; -.
DR   EPD; P25445; -.
DR   MaxQB; P25445; -.
DR   PaxDb; P25445; -.
DR   PeptideAtlas; P25445; -.
DR   PRIDE; P25445; -.
DR   TopDownProteomics; P25445-7; -. [P25445-7]
DR   DNASU; 355; -.
DR   Ensembl; ENST00000355279; ENSP00000347426; ENSG00000026103. [P25445-7]
DR   Ensembl; ENST00000355740; ENSP00000347979; ENSG00000026103. [P25445-1]
DR   Ensembl; ENST00000357339; ENSP00000349896; ENSG00000026103. [P25445-6]
DR   Ensembl; ENST00000479522; ENSP00000424113; ENSG00000026103. [P25445-3]
DR   Ensembl; ENST00000484444; ENSP00000420975; ENSG00000026103. [P25445-2]
DR   Ensembl; ENST00000488877; ENSP00000425159; ENSG00000026103. [P25445-4]
DR   Ensembl; ENST00000492756; ENSP00000422453; ENSG00000026103. [P25445-5]
DR   Ensembl; ENST00000494410; ENSP00000423755; ENSG00000026103. [P25445-4]
DR   GeneID; 355; -.
DR   KEGG; hsa:355; -.
DR   UCSC; uc001kfr.4; human. [P25445-1]
DR   CTD; 355; -.
DR   DisGeNET; 355; -.
DR   GeneCards; FAS; -.
DR   GeneReviews; FAS; -.
DR   HGNC; HGNC:11920; FAS.
DR   HPA; HPA027444; -.
DR   MalaCards; FAS; -.
DR   MIM; 134637; gene.
DR   MIM; 601859; phenotype.
DR   neXtProt; NX_P25445; -.
DR   OpenTargets; ENSG00000026103; -.
DR   Orphanet; 3261; Autoimmune lymphoproliferative syndrome.
DR   Orphanet; 85408; Juvenile rheumatoid factor-negative polyarthritis.
DR   Orphanet; 85410; Oligoarticular juvenile arthritis.
DR   PharmGKB; PA36613; -.
DR   eggNOG; ENOG410J23A; Eukaryota.
DR   eggNOG; ENOG4112ADB; LUCA.
DR   GeneTree; ENSGT00730000111280; -.
DR   HOGENOM; HOG000139681; -.
DR   HOVERGEN; HBG004091; -.
DR   InParanoid; P25445; -.
DR   KO; K04390; -.
DR   OMA; CTTCEHG; -.
DR   OrthoDB; EOG091G0DU6; -.
DR   PhylomeDB; P25445; -.
DR   TreeFam; TF333916; -.
DR   Reactome; R-HSA-140534; Ligand-dependent caspase activation.
DR   Reactome; R-HSA-3371378; Regulation by c-FLIP.
DR   Reactome; R-HSA-5213460; RIPK1-mediated regulated necrosis.
DR   Reactome; R-HSA-5218900; CASP8 activity is inhibited.
DR   Reactome; R-HSA-6803211; TP53 Regulates Transcription of Death Receptors and Ligands.
DR   Reactome; R-HSA-69416; Dimerization of procaspase-8.
DR   Reactome; R-HSA-75157; FasL/ CD95L signaling.
DR   SIGNOR; P25445; -.
DR   EvolutionaryTrace; P25445; -.
DR   GeneWiki; Fas_receptor; -.
DR   GenomeRNAi; 355; -.
DR   PMAP-CutDB; P25445; -.
DR   PRO; PR:P25445; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   Bgee; ENSG00000026103; -.
DR   CleanEx; HS_FAS; -.
DR   ExpressionAtlas; P25445; baseline and differential.
DR   Genevisible; P25445; HS.
DR   GO; GO:0031265; C:CD95 death-inducing signaling complex; IDA:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0031264; C:death-inducing signaling complex; IDA:UniProtKB.
DR   GO; GO:0009897; C:external side of plasma membrane; IEA:Ensembl.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0045121; C:membrane raft; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IBA:GO_Central.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0005516; F:calmodulin binding; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0019900; F:kinase binding; IPI:BHF-UCL.
DR   GO; GO:0004872; F:receptor activity; TAS:ProtInc.
DR   GO; GO:0004871; F:signal transducer activity; TAS:ProtInc.
DR   GO; GO:0043120; F:tumor necrosis factor binding; IBA:GO_Central.
DR   GO; GO:0005031; F:tumor necrosis factor-activated receptor activity; IBA:GO_Central.
DR   GO; GO:0006919; P:activation of cysteine-type endopeptidase activity involved in apoptotic process; TAS:Reactome.
DR   GO; GO:0097296; P:activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway; TAS:Reactome.
DR   GO; GO:0006924; P:activation-induced cell death of T cells; IEA:Ensembl.
DR   GO; GO:0006915; P:apoptotic process; IDA:MGI.
DR   GO; GO:0097190; P:apoptotic signaling pathway; TAS:Reactome.
DR   GO; GO:0019724; P:B cell mediated immunity; IEA:Ensembl.
DR   GO; GO:0034198; P:cellular response to amino acid starvation; IMP:CAFA.
DR   GO; GO:0071455; P:cellular response to hyperoxia; IMP:UniProtKB.
DR   GO; GO:0071285; P:cellular response to lithium ion; IEA:Ensembl.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEP:UniProtKB.
DR   GO; GO:0007623; P:circadian rhythm; IEA:Ensembl.
DR   GO; GO:0097191; P:extrinsic apoptotic signaling pathway; IMP:UniProtKB.
DR   GO; GO:0097192; P:extrinsic apoptotic signaling pathway in absence of ligand; IEA:Ensembl.
DR   GO; GO:0008625; P:extrinsic apoptotic signaling pathway via death domain receptors; IEA:Ensembl.
DR   GO; GO:0036337; P:Fas signaling pathway; IMP:CAFA.
DR   GO; GO:0010467; P:gene expression; IEA:Ensembl.
DR   GO; GO:0097284; P:hepatocyte apoptotic process; IEA:Ensembl.
DR   GO; GO:0006955; P:immune response; IBA:GO_Central.
DR   GO; GO:0002377; P:immunoglobulin production; IEA:Ensembl.
DR   GO; GO:0006925; P:inflammatory cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0006954; P:inflammatory response; IBA:GO_Central.
DR   GO; GO:0097049; P:motor neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0007275; P:multicellular organism development; IBA:GO_Central.
DR   GO; GO:0097527; P:necroptotic signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; TAS:ProtInc.
DR   GO; GO:0050869; P:negative regulation of B cell activation; IEA:Ensembl.
DR   GO; GO:1902042; P:negative regulation of extrinsic apoptotic signaling pathway via death domain receptors; TAS:Reactome.
DR   GO; GO:0045060; P:negative thymic T cell selection; IEA:Ensembl.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:2001235; P:positive regulation of apoptotic signaling pathway; IMP:CAFA.
DR   GO; GO:2001269; P:positive regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway; IMP:CAFA.
DR   GO; GO:2001241; P:positive regulation of extrinsic apoptotic signaling pathway in absence of ligand; IEA:Ensembl.
DR   GO; GO:0070230; P:positive regulation of lymphocyte apoptotic process; IEA:Ensembl.
DR   GO; GO:0032464; P:positive regulation of protein homooligomerization; IEA:Ensembl.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IMP:CAFA.
DR   GO; GO:0006461; P:protein complex assembly; TAS:ProtInc.
DR   GO; GO:0051260; P:protein homooligomerization; IEA:Ensembl.
DR   GO; GO:0042981; P:regulation of apoptotic process; TAS:Reactome.
DR   GO; GO:0042127; P:regulation of cell proliferation; IBA:GO_Central.
DR   GO; GO:1902041; P:regulation of extrinsic apoptotic signaling pathway via death domain receptors; TAS:Reactome.
DR   GO; GO:0045619; P:regulation of lymphocyte differentiation; IEA:Ensembl.
DR   GO; GO:0045637; P:regulation of myeloid cell differentiation; IEA:Ensembl.
DR   GO; GO:0032872; P:regulation of stress-activated MAPK cascade; IMP:CAFA.
DR   GO; GO:0003014; P:renal system process; IEA:Ensembl.
DR   GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IBA:GO_Central.
DR   GO; GO:0009636; P:response to toxic substance; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0048536; P:spleen development; IEA:Ensembl.
DR   CDD; cd08316; Death_FAS_TNFRSF6; 1.
DR   CDD; cd10579; TNFRSF6; 1.
DR   InterPro; IPR011029; DEATH-like_dom.
DR   InterPro; IPR000488; Death_domain.
DR   InterPro; IPR008063; Fas_rcpt.
DR   InterPro; IPR001368; TNFR/NGFR_Cys_rich_reg.
DR   InterPro; IPR033998; TNFRSF6_death.
DR   InterPro; IPR033999; TNFRSF6_N.
DR   PANTHER; PTHR23097:SF158; PTHR23097:SF158; 1.
DR   Pfam; PF00531; Death; 1.
DR   Pfam; PF00020; TNFR_c6; 2.
DR   PRINTS; PR01680; TNFACTORR6.
DR   SMART; SM00005; DEATH; 1.
DR   SMART; SM00208; TNFR; 3.
DR   SUPFAM; SSF47986; SSF47986; 1.
DR   PROSITE; PS50017; DEATH_DOMAIN; 1.
DR   PROSITE; PS00652; TNFR_NGFR_1; 2.
DR   PROSITE; PS50050; TNFR_NGFR_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; Calmodulin-binding;
KW   Cell membrane; Complete proteome; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; Glycoprotein; Membrane;
KW   Phosphoprotein; Polymorphism; Receptor; Reference proteome; Repeat;
KW   Secreted; Signal; Transmembrane; Transmembrane helix.
FT   SIGNAL        1     25       {ECO:0000255}.
FT   CHAIN        26    335       Tumor necrosis factor receptor
FT                                superfamily member 6.
FT                                /FTId=PRO_0000034563.
FT   TOPO_DOM     26    173       Extracellular. {ECO:0000255}.
FT   TRANSMEM    174    190       Helical. {ECO:0000255}.
FT   TOPO_DOM    191    335       Cytoplasmic. {ECO:0000255}.
FT   REPEAT       47     83       TNFR-Cys 1.
FT   REPEAT       84    127       TNFR-Cys 2.
FT   REPEAT      128    166       TNFR-Cys 3.
FT   DOMAIN      230    314       Death. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00064}.
FT   REGION      212    317       Interaction with HIPK3. {ECO:0000250}.
FT   REGION      230    254       Interaction with CALM.
FT                                {ECO:0000269|PubMed:24914971}.
FT   MOD_RES     209    209       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     214    214       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P25446}.
FT   MOD_RES     225    225       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   CARBOHYD     28     28       O-linked (GalNAc...) threonine.
FT                                {ECO:0000269|PubMed:22171320}.
FT   CARBOHYD    118    118       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    136    136       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     59     73       {ECO:0000255|PROSITE-ProRule:PRU00206}.
FT   DISULFID     63     82       {ECO:0000255|PROSITE-ProRule:PRU00206}.
FT   DISULFID     85    101       {ECO:0000255|PROSITE-ProRule:PRU00206}.
FT   DISULFID    104    119       {ECO:0000255|PROSITE-ProRule:PRU00206}.
FT   DISULFID    107    127       {ECO:0000255|PROSITE-ProRule:PRU00206}.
FT   DISULFID    129    143       {ECO:0000255|PROSITE-ProRule:PRU00206}.
FT   DISULFID    146    157       {ECO:0000255|PROSITE-ProRule:PRU00206}.
FT   DISULFID    149    165       {ECO:0000255|PROSITE-ProRule:PRU00206}.
FT   VAR_SEQ      66    103       GERKARDCTVNGDEPDCVPCQEGKEYTDKAHFSSKCRR ->
FT                                DVNMESSRNAHSPATPSAKRKDPDLTWGGFVFFFCQFH
FT                                (in isoform 2).
FT                                {ECO:0000303|PubMed:7533181,
FT                                ECO:0000303|PubMed:7575433}.
FT                                /FTId=VSP_006481.
FT   VAR_SEQ      66     86       GERKARDCTVNGDEPDCVPCQ -> DVNMESSRNAHSPATP
FT                                SAKRK (in isoform 3).
FT                                {ECO:0000303|PubMed:7533181,
FT                                ECO:0000303|PubMed:7575433}.
FT                                /FTId=VSP_006483.
FT   VAR_SEQ      87    335       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:7533181,
FT                                ECO:0000303|PubMed:7575433}.
FT                                /FTId=VSP_006484.
FT   VAR_SEQ     104    335       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:7533181,
FT                                ECO:0000303|PubMed:7575433}.
FT                                /FTId=VSP_006482.
FT   VAR_SEQ     112    149       GLEVEINCTRTQNTKCRCKPNFFCNSTVCEHCDPCTKC ->
FT                                DVNMESSRNAHSPATPSAKRKDPDLTWGGFVFFFCQFH
FT                                (in isoform 4).
FT                                {ECO:0000303|PubMed:7575433,
FT                                ECO:0000303|PubMed:8648105}.
FT                                /FTId=VSP_006485.
FT   VAR_SEQ     112    132       GLEVEINCTRTQNTKCRCKPN -> DVNMESSRNAHSPATP
FT                                SAKRK (in isoform 5).
FT                                {ECO:0000303|PubMed:8648105,
FT                                ECO:0000303|Ref.8}.
FT                                /FTId=VSP_006487.
FT   VAR_SEQ     133    335       Missing (in isoform 5).
FT                                {ECO:0000303|PubMed:8648105,
FT                                ECO:0000303|Ref.8}.
FT                                /FTId=VSP_006488.
FT   VAR_SEQ     150    335       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:7575433,
FT                                ECO:0000303|PubMed:8648105}.
FT                                /FTId=VSP_006486.
FT   VAR_SEQ     169    189       Missing (in isoform 6).
FT                                {ECO:0000303|PubMed:7533181,
FT                                ECO:0000303|PubMed:7575433}.
FT                                /FTId=VSP_006489.
FT   VAR_SEQ     218    220       ETV -> MLT (in isoform 7).
FT                                {ECO:0000303|PubMed:8598453}.
FT                                /FTId=VSP_045235.
FT   VAR_SEQ     221    335       Missing (in isoform 7).
FT                                {ECO:0000303|PubMed:8598453}.
FT                                /FTId=VSP_045236.
FT   VARIANT      16     16       A -> T (in dbSNP:rs3218619).
FT                                {ECO:0000269|Ref.11}.
FT                                /FTId=VAR_020008.
FT   VARIANT      25     25       A -> T (in non-Hodgkin lymphoma; somatic
FT                                mutation; dbSNP:rs606231364).
FT                                {ECO:0000269|PubMed:9787134}.
FT                                /FTId=VAR_013416.
FT   VARIANT      28     28       T -> A (in ALPS1A; associated with
FT                                autoimmune hepatitis type 2).
FT                                {ECO:0000269|PubMed:9322534}.
FT                                /FTId=VAR_013417.
FT   VARIANT      82     82       C -> R (in ALPS1A).
FT                                {ECO:0000269|PubMed:9927496}.
FT                                /FTId=VAR_013418.
FT   VARIANT     118    118       N -> S (in squamous cell carcinoma; burn-
FT                                scar related; somatic mutation;
FT                                dbSNP:rs121913083).
FT                                {ECO:0000269|PubMed:10620127}.
FT                                /FTId=VAR_018321.
FT   VARIANT     121    121       R -> W (in ALPS1A; dbSNP:rs121913078).
FT                                {ECO:0000269|PubMed:9028321}.
FT                                /FTId=VAR_013419.
FT   VARIANT     122    122       T -> I (in dbSNP:rs3218614).
FT                                {ECO:0000269|Ref.11}.
FT                                /FTId=VAR_020009.
FT   VARIANT     178    178       C -> R (in squamous cell carcinoma; burn-
FT                                scar related; somatic mutation;
FT                                dbSNP:rs121913084).
FT                                {ECO:0000269|PubMed:10620127}.
FT                                /FTId=VAR_018322.
FT   VARIANT     180    180       L -> F (in non-Hodgkin lymphoma; somatic
FT                                mutation). {ECO:0000269|PubMed:9787134}.
FT                                /FTId=VAR_013420.
FT   VARIANT     183    183       P -> L (in non-Hodgkin lymphoma; somatic
FT                                mutation; dbSNP:rs758835365).
FT                                {ECO:0000269|PubMed:9787134}.
FT                                /FTId=VAR_013421.
FT   VARIANT     184    184       I -> V (in dbSNP:rs28362322).
FT                                /FTId=VAR_052347.
FT   VARIANT     198    198       T -> I (in non-Hodgkin lymphoma; somatic
FT                                mutation). {ECO:0000269|PubMed:9787134}.
FT                                /FTId=VAR_013422.
FT   VARIANT     232    232       Y -> C (in ALPS1A; no effect on
FT                                interaction with FADD;
FT                                dbSNP:rs121913079).
FT                                {ECO:0000269|PubMed:20935634,
FT                                ECO:0000269|PubMed:9028321}.
FT                                /FTId=VAR_013423.
FT   VARIANT     241    241       T -> K (in ALPS1A; dbSNP:rs201072885).
FT                                {ECO:0000269|PubMed:10090885}.
FT                                /FTId=VAR_013424.
FT   VARIANT     241    241       T -> P (in ALPS1A; dbSNP:rs121913076).
FT                                {ECO:0000269|PubMed:11418480,
FT                                ECO:0000269|PubMed:7540117}.
FT                                /FTId=VAR_013425.
FT   VARIANT     249    249       V -> L (in ALPS1A).
FT                                {ECO:0000269|PubMed:10515860}.
FT                                /FTId=VAR_065128.
FT   VARIANT     250    250       R -> P (in ALPS1A; dbSNP:rs121913080).
FT                                {ECO:0000269|PubMed:10515860,
FT                                ECO:0000269|PubMed:9927496}.
FT                                /FTId=VAR_013426.
FT   VARIANT     250    250       R -> Q (in ALPS1A; no effect on
FT                                interaction with FADD).
FT                                {ECO:0000269|PubMed:10090885,
FT                                ECO:0000269|PubMed:20935634}.
FT                                /FTId=VAR_013427.
FT   VARIANT     253    253       G -> D (in ALPS1A).
FT                                {ECO:0000269|PubMed:10515860}.
FT                                /FTId=VAR_065129.
FT   VARIANT     253    253       G -> S (in ALPS1A).
FT                                {ECO:0000269|PubMed:10515860}.
FT                                /FTId=VAR_065130.
FT   VARIANT     255    255       N -> D (in squamous cell carcinoma; burn-
FT                                scar related; somatic mutation;
FT                                dbSNP:rs121913082).
FT                                {ECO:0000269|PubMed:10620127}.
FT                                /FTId=VAR_018323.
FT   VARIANT     257    257       A -> D (in ALPS1A; loss of interaction
FT                                with FADD). {ECO:0000269|PubMed:20935634,
FT                                ECO:0000269|PubMed:9028957}.
FT                                /FTId=VAR_013428.
FT   VARIANT     259    259       I -> R (in ALPS1A).
FT                                {ECO:0000269|PubMed:10515860}.
FT                                /FTId=VAR_065131.
FT   VARIANT     260    260       D -> G (in ALPS1A).
FT                                {ECO:0000269|PubMed:9927496}.
FT                                /FTId=VAR_013429.
FT   VARIANT     260    260       D -> V (in ALPS1A; also found in non-
FT                                Hodgkin lymphoma; somatic mutation; loss
FT                                of interaction with FADD;
FT                                dbSNP:rs28929498).
FT                                {ECO:0000269|PubMed:11418480,
FT                                ECO:0000269|PubMed:20935634,
FT                                ECO:0000269|PubMed:9787134,
FT                                ECO:0000269|PubMed:9821419}.
FT                                /FTId=VAR_013431.
FT   VARIANT     260    260       D -> Y (in ALPS1A; loss of interaction
FT                                with FADD; dbSNP:rs121913086).
FT                                {ECO:0000269|PubMed:20935634,
FT                                ECO:0000269|PubMed:8929361}.
FT                                /FTId=VAR_013430.
FT   VARIANT     262    262       I -> S (in ALPS1A).
FT                                {ECO:0000269|PubMed:17336828}.
FT                                /FTId=VAR_058910.
FT   VARIANT     264    264       N -> K (in non-Hodgkin lymphoma; somatic
FT                                mutation). {ECO:0000269|PubMed:9787134}.
FT                                /FTId=VAR_013432.
FT   VARIANT     270    270       T -> I (in ALPS1A; dbSNP:rs121913081).
FT                                {ECO:0000269|PubMed:11418480,
FT                                ECO:0000269|PubMed:9927496}.
FT                                /FTId=VAR_013433.
FT   VARIANT     270    270       T -> K (in ALPS1A; loss of interaction
FT                                with FADD). {ECO:0000269|PubMed:10515860,
FT                                ECO:0000269|PubMed:20935634}.
FT                                /FTId=VAR_065132.
FT   VARIANT     272    272       E -> G (in ALPS1A).
FT                                {ECO:0000269|PubMed:10340403,
FT                                ECO:0000269|PubMed:11418480}.
FT                                /FTId=VAR_013434.
FT   VARIANT     272    272       E -> K (in ALPS1A; also found in non-
FT                                Hodgkin lymphoma; somatic mutation; loss
FT                                of interaction with FADD).
FT                                {ECO:0000269|PubMed:10515860,
FT                                ECO:0000269|PubMed:20935634,
FT                                ECO:0000269|PubMed:9787134}.
FT                                /FTId=VAR_013435.
FT   VARIANT     278    278       L -> F (in non-Hodgkin lymphoma; somatic
FT                                mutation). {ECO:0000269|PubMed:9787134}.
FT                                /FTId=VAR_013436.
FT   VARIANT     299    299       K -> N (in non-Hodgkin lymphoma; somatic
FT                                mutation). {ECO:0000269|PubMed:9787134}.
FT                                /FTId=VAR_013437.
FT   VARIANT     305    305       T -> I (in dbSNP:rs3218611).
FT                                {ECO:0000269|Ref.11}.
FT                                /FTId=VAR_020942.
FT   VARIANT     310    310       I -> S (in ALPS1A).
FT                                {ECO:0000269|PubMed:9028957}.
FT                                /FTId=VAR_013438.
FT   MUTAGEN     250    250       R->E: Strongly decreased interaction with
FT                                FADD. {ECO:0000269|PubMed:20935634}.
FT   MUTAGEN     261    261       E->K: Loss of interaction with FADD.
FT                                {ECO:0000269|PubMed:20935634}.
FT   MUTAGEN     283    283       Q->K: Loss of interaction with FADD.
FT                                {ECO:0000269|PubMed:20935634}.
FT   MUTAGEN     287    287       K->D: Strongly decreased interaction with
FT                                FADD. {ECO:0000269|PubMed:20935634}.
FT   MUTAGEN     291    291       Y->D: Decreased interaction with FADD.
FT                                {ECO:0000269|PubMed:19118384}.
FT   MUTAGEN     313    313       I->D: Constitutive activation. Promotes
FT                                apoptosis, both in the presence and in
FT                                the absence of stimulation by a ligand.
FT                                {ECO:0000269|PubMed:19118384}.
FT   CONFLICT    224    224       L -> F (in Ref. 11; AAR08906).
FT                                {ECO:0000305}.
FT   CONFLICT    242    242       L -> P (in Ref. 9; CAR92543).
FT                                {ECO:0000305}.
FT   STRAND       67     71       {ECO:0000244|PDB:3TJE}.
FT   STRAND       75     77       {ECO:0000244|PDB:3TJE}.
FT   STRAND       82     84       {ECO:0000244|PDB:3TJE}.
FT   TURN         87     89       {ECO:0000244|PDB:3TJE}.
FT   HELIX       109    111       {ECO:0000244|PDB:3TJE}.
FT   STRAND      113    117       {ECO:0000244|PDB:3TJE}.
FT   STRAND      126    129       {ECO:0000244|PDB:3TJE}.
FT   STRAND      137    139       {ECO:0000244|PDB:3TJE}.
FT   HELIX       174    181       {ECO:0000244|PDB:2NA7}.
FT   HELIX       184    193       {ECO:0000244|PDB:2NA7}.
FT   HELIX       232    242       {ECO:0000244|PDB:3EWT}.
FT   TURN        251    253       {ECO:0000244|PDB:1DDF}.
FT   HELIX       256    265       {ECO:0000244|PDB:3EZQ}.
FT   HELIX       270    282       {ECO:0000244|PDB:3EZQ}.
FT   HELIX       287    319       {ECO:0000244|PDB:3EZQ}.
FT   HELIX       327    334       {ECO:0000244|PDB:3EZQ}.
SQ   SEQUENCE   335 AA;  37732 MW;  0139942535111410 CRC64;
     MLGIWTLLPL VLTSVARLSS KSVNAQVTDI NSKGLELRKT VTTVETQNLE GLHHDGQFCH
     KPCPPGERKA RDCTVNGDEP DCVPCQEGKE YTDKAHFSSK CRRCRLCDEG HGLEVEINCT
     RTQNTKCRCK PNFFCNSTVC EHCDPCTKCE HGIIKECTLT SNTKCKEEGS RSNLGWLCLL
     LLPIPLIVWV KRKEVQKTCR KHRKENQGSH ESPTLNPETV AINLSDVDLS KYITTIAGVM
     TLSQVKGFVR KNGVNEAKID EIKNDNVQDT AEQKVQLLRN WHQLHGKKEA YDTLIKDLKK
     ANLCTLAEKI QTIILKDITS DSENSNFRNE IQSLV
//
